Sign in to view content

Anti-VEGF treatment switch in DME and nAMD: a comparison of aflibercept versus ranibizumab after a single-dose switch

Estephania Feria, MD

Video
Published 2019

Related

Apples and Oranges: "Real-World" Outcomes Differ From Clinical Trial Outcomes Because "Real-World" Patients Differ From Clinical Trial Patients
Franco M. Recchia, MD
Annual Meeting Talks
2021
Fluctuations in Central Subfield Thickness Associated With Worse Visual Outcomes in Patients With Diabetic Macular Edema in Clinical Trial Setting
Matthew Starr, MD
Updates from the Field
2021
Episode 14: Plasma VEGF Levels After Anti-VEGF Injections (DRCR protocol T) with Dr. Charles Wykoff
Keyvan Koushan, MD, FRCSC
Member Podcasts
2018

Category: AMD-Neovascular

See more